Evidence map›Paper›PMID 37219908›Full record

ArticleJAMA network open2023

Clinical Characteristics and Outcomes of Cancer Cases Among Syrian Refugees From Southern Turkey.

Tezer Kutluk, Berksoy Sahin, Meral Kirazli, Fahad Ahmed, Sinem Aydin, Havva Yesil Çinkir, Gülay Sezgin, Ibrahim Bayram, Senar Ebinç, Abdurrahman Isikdogan and 23 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 12 institutions in 2 countries.

Tezer KutlukDepartment of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.
Berksoy SahinDepartment of Medical Oncology, Çukurova University, Adana, Turkey.
Meral KirazliDepartment of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.
Fahad AhmedDepartment of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.
Sinem AydinDepartment of Pediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.
Havva Yesil ÇinkirDepartment of Medical Oncology, Gaziantep University, Gaziantep, Turkey.
Gülay SezginDepartment of Pediatric Hematology-Oncology, Çukurova University, Adana, Turkey.
Ibrahim BayramDepartment of Pediatric Hematology-Oncology, Çukurova University, Adana, Turkey.
Senar EbinçDepartment of Medical Oncology, Dicle University, Diyarbakır, Turkey.
Abdurrahman IsikdoganDepartment of Medical Oncology, Dicle University, Diyarbakır, Turkey.
Ilgen SasmazDepartment of Pediatric Hematology, Çukurova University, Adana, Turkey.
Vahap OkanDepartment of Hematology, Gaziantep University, Gaziantep, Turkey.
Gül IlhanDepartment of Hematology, Mustafa Kemal University, Hatay, Turkey.
Ayse Ceyda ÖrenDepartment of Pediatric Hematology-Oncology, Gaziantep University, Gaziantep, Turkey.
Sinan AkbayramDepartment of Pediatric Hematology-Oncology, Gaziantep University, Gaziantep, Turkey.
Hakan HarputluogluDepartment of Medical Oncology, İnönü University, Malatya, Turkey.
Cihan UralDepartment of Hematology, Dicle University, Diyarbakır, Turkey.
Orhan AyyildizDepartment of Hematology, Dicle University, Diyarbakır, Turkey.
Gökmen AktasDepartment of Medical Oncology, Sütçü İmam University, Kahramanmaraş, Turkey.
Mehmet Ali UçarDepartment of Hematology, Çukurova University, Adana, Turkey.
Birol GüvençDepartment of Hematology, Çukurova University, Adana, Turkey.
Dogan KöseDepartment of Pediatric Oncology, Harran University, Şanlıurfa, Turkey.
Can AcipayamDepartment of Pediatric Hematology-Oncology, Sütçü İmam University, Kahramanmaraş, Turkey.
Sabri GüncanDepartment of Medical Oncology, Mersin University, Mersin, Turkey.
Vehbi ErçolakDepartment of Medical Oncology, Mersin University, Mersin, Turkey.
Ilhami BerberDepartment of Hematology, İnönü University, Malatya, Turkey.
Aydan AkdenizDepartment of Hematology, Mersin University, Mersin, Turkey.
Arzu AkyayDepartment of Pediatric Hematology-Oncology, İnönü University, Malatya, Turkey.
Veysiye Hülya ÜzelDepartment of Pediatric Hematology-Oncology, Dicle University, Diyarbakır, Turkey.
Murat SökerDepartment of Pediatric Hematology-Oncology, Dicle University, Diyarbakır, Turkey.
Meltem SengelenDepartment of Public Health, Hacettepe University, Ankara, Turkey.
Suayib YalçinDepartment of Medical Oncology, Hacettepe University, Ankara, Turkey.
Richard SullivanKing's College London, Institute of Cancer Policy, Conflict & Health Research Group, London, United Kingdom.
Cukurova University · TRDicle University · TRHacettepe University · TRGaziantep University · TRInonu University · TRMersin Üniversitesi · TRAnkara Yıldırım Beyazıt University · TRKahramanmaraş Sütçü İmam University · TRKing's College London · GBMedical Park Gaziantep Hospital · TRMustafa Kemal University · TRSema Hospital · TR

Funding

Department of Health NIHR131207
6 · The paper itself

Abstract

Importance: Cancer was a common noncommunicable disease in Syria before the present conflict and is now a major disease burden among 3.6 million Syrian refugees in Turkey. Data to inform health care practice are needed. Objective: To explore sociodemographic characteristics, clinical characteristics, and treatment outcomes of Syrian patients with cancer residing in the southern border provinces of Turkey hosting more than 50% of refugees. Design, Setting, and Participants: This was a retrospective hospital-based cross-sectional study. The study sample consisted of all adult and children Syrian refugees diagnosed and/or treated for cancer between January 1, 2011, and December 31, 2020, in hematology-oncology departments of 8 university hospitals in the Southern province of Turkey. Data were analyzed from May 1, 2022, to September 30, 2022. Main Outcomes and Measures: Demographic characteristics (date of birth, sex, and residence), date of first cancer-related symptom, date and place of diagnosis, disease status at first presentation, treatment modalities, date and status at last hospital visit, and date of death. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision and International Classification of Childhood Cancers, Third Edition, were used for the classification of cancer. The Surveillance, Epidemiology, and End Results system was applied for staging. The diagnostic interval was defined as the number of days from first symptoms until the diagnosis. Treatment abandonment was documented if the patient did not attend the clinic within 4 weeks of a prescribed appointment throughout the treatment. Results: A total of 1114 Syrian adult and 421 Syrian children with cancer were included. The median age at diagnosis was 48.2 (IQR, 34.2-59.4) years for adults and 5.7 (IQR, 3.1-10.7) years for children. The median diagnostic interval was 66 (IQR, 26.5-114.3) days for adults and 28 (IQR, 14.0-69.0) days for children. Breast cancer (154 [13.8%]), leukemia and multiple myeloma (147 [13.2%]), and lymphoma (141 [12.7%]) were common among adults, and leukemias (180 [42.8%]), lymphomas (66 [15.7%]), and central nervous system neoplasms (40 [9.5%]) were common among children. The median follow-up time was 37.5 (IQR, 32.6-42.3) months for adults and 25.4 (IQR, 20.9-29.9) months for children. The 5-year survival rate was 17.5% in adults and 29.7% in children. Conclusions and Relevance: Despite universal health coverage and investment in the health care system, low survival rates were reported in this study for both adults and children with cancer. These findings suggest that cancer care in refugees requires novel planning within national cancer control programs with global cooperation.

Indexed as

LeukemiaRefugeesAdultAmbulatory Care FacilitiesChildCross-Sectional StudiesHospitals, UniversityHumansRetrospective StudiesSyriaTurkey

Identifiers

PMID37219908
PMCPMC10208156
OpenAlexW4377564717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.